Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes

Paolo Di Bartolo, Francesca Pellicano, Antonio Scaramuzza, Cipriana Sardu, Tino Casetti, Emanuele Bosi, Valerio Miselli, Sara Brandolini, Tiziano Fabbri, Piero Meandri, Francesco Cannatà

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Persistent glucose variability is a frequent condition in type 1 diabetes. Continuous subcutaneous insulin infusion (CSII) is a rational option to overcome this clinical issue; however, no comparative studies have been reported for aspart and lispro insulin when used in CSII. This study compare the effects of aspart and lispro delivered by CSII on glycemic stability as measured using a continuous glucose monitoring system. Methods: This single-center, randomized, controlled, 3-day crossover trial included 17 patients with type 1 diabetes. Patients were randomized to receive insulin aspart or insulin lispro. The next day, they received a standard meal at breakfast and lunch and a bolus of insulin aspart or lispro based on insulin:carbohydrate ratio. Patients were monitored for 8 h, after which they received a crossover treatment with insulin aspart or insulin lispro followed by the same procedure as previously. Results: Postprandial blood glucose was more stable with insulin aspart than insulin lispro (absolute Δglucose 7.04 ± 3.16 vs. 9.04 ± 4.2, P <0.0019). Daily blood glucose variability profiles (coefficient of variation and mean amplitude of glucose excursion) and frequency of hypoglycemic episodes (area under the curve

Original languageEnglish
Pages (from-to)495-498
Number of pages4
JournalDiabetes Technology and Therapeutics
Volume10
Issue number6
DOIs
Publication statusPublished - Dec 1 2008

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medical Laboratory Technology

Fingerprint

Dive into the research topics of 'Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes'. Together they form a unique fingerprint.

Cite this